RGX-202 demonstrated significant functional improvements in DMD patients, surpassing natural history controls in key assessments like the North Star Ambulatory Assessment. High microdystrophin ...
Alignment achieved with FDA on AFFINITY DUCHENNE ® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above ...
The last time I spoke about REGENXBIO (RGNX), it was with respect to a Seeking Alpha article entitled "Regenxbio: With Additional MPS II Data, Program Advancement Remains On Track". With respect to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results